Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More
Portfolio Pulse from Lara Goldstein
MAPS Public Benefit Corporation, a subsidiary of MAPS, has raised over $100M in Series A funding to support FDA approval of MDMA for PTSD treatment. The U.S. Department of Veterans Affairs is funding psychedelic research for veterans with PTSD and depression. A list of 30 influential figures in psychedelics for 2024 was highlighted. Psychedelics policy reform is advancing in 13 states. Psychedelics stocks and ETFs showed varied performance, with some like GH Research and Atai Life Sciences closing higher, while others like Clearmind Medicine saw a decline.
January 12, 2024 | 9:55 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Atai Life Sciences (ATAI) closed higher, potentially benefiting from the positive news flow in the psychedelics industry.
The increase in ATAI's stock price could be a reaction to the overall positive developments in the psychedelics industry, including regulatory advancements and increased funding.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
GH Research (GHRS) closed higher, reflecting positive investor sentiment possibly due to the company's progress or the sector's positive developments.
GHRS's increase in closing price may be attributed to positive investor sentiment towards the company's developments or the broader psychedelics sector's advancements.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
AdvisorShares Psychedelics ETF (PSIL) showed a positive weekly performance, closing higher than the previous weeks, indicating investor optimism in the psychedelics sector.
The positive closing of PSIL suggests that the recent developments in the psychedelics sector, including MAPS PBC's funding and VA's research initiative, may be contributing to increased investor confidence, potentially leading to a short-term uptick in the ETF's performance.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Clearmind Medicine (CMND) experienced a significant drop in closing price, which may indicate investor skepticism or negative market reaction to company-specific news.
CMND's considerable fall in stock price could reflect investor skepticism or a negative reaction to specific news about the company, despite the sector's positive momentum.
CONFIDENCE 75
IMPORTANCE 65
RELEVANCE 70
NEGATIVE IMPACT
COMPASS Pathways (CMPS) closed lower than previous weeks, indicating potential investor concerns or profit-taking after recent gains.
The decline in CMPS's closing price, despite the overall positive news in the psychedelics sector, could be due to investors locking in profits after previous gains or concerns about the company's specific prospects.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 70